Rassembler et fédérer tous les acteurs au service de la filière
YOUR GENOMIC EXPERT FOR BIOLOGICS TESTING
Robust and efficient Quality Control testing is critical for the development of biologics in order to reduce time to market and improve patient outcomes.
Developers and producers need QC testing solutions that help de-risk their product development pipeline by preventing adventitious agent contamination and cell line misidentification.
To meet those objectives, PathoQuest offers advanced Next Generation Sequencing (NGS) solutions that supplement or replace traditional methods and support the strategic decision-making process. This innovative approach allows for a robust and unambiguous level of testing and for faster turnaround time and is available with GLP grade.
PATHOQUEST NGS SOLUTIONS IN 5 QUICK FACTS:
Request the full brochure at email@example.com
Keen on learning more about challenges for adventitious virus detection and how standardized NGS method is the solution for the qualification of your biological production?
PathoQuest offers advanced Next Generation Sequencing (NGS) solutions that supplement or replace traditional methods and support the strategic decision-making process.
PathoQuest’s NGS-based adventitious virus testing approach uses a process called metagenomics to provide sensitive and comprehensive services for the identification of pathogens.
PathoQuest’s NGS-based genetic characterization testing approach uses the power and robustness of high-throughput sequencing to provide a comprehensive approach to the characterization of biologics intermediates, vaccines, and cell & gene therapy products.
PathoQuest NGS innovative approach provides biotech and biopharma companies developing advanced therapy medicinal products (ATMPs), vaccines and other biologicals with robust and unambiguous level of testing and with faster turnaround time.
Greater detection for better decisions
Customized, fast, reliable, cost-effective
– Broad range detection of viruses
– Genetic drift of vaccine stocks
– Assess highly concentrated stocks
– Trancriptomic NGS approach on MCB
– Reduce the risk of false positives
– Identity & Clonality documentation
GENE & CELL THERAPY
– Signature of viral replication
– High precision genetic characterization
– Insertion site / flanking regions sequencing
Ensure the highest safety for your biologic products by de risking the drug development pipeline.